HIV / AIDS
Coverage of the 2017 IAS Conference on HIV Science
- Details
- Category: HIV Treatment
- Published on Monday, 31 July 2017 00:00
HIVandHepatitis.com coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.
Antiretroviral Therapy
- Doravirine Combo Pill Looks Good for Initial HIV Treatment
- Boosted Darunavir Plus Lamivudine Matches 3-Drug Regimen
- Trans Women Wary of Antiretroviral Drug and Hormone Interactions
- Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP
- First Protease Inhibitor Combo Pill Maintains Viral Suppression
- Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
- New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment IAS
HIV Cure Research
- Cancer Research May Offer Clues for HIV Cure Research -- and Vice Versa
- Why Curing Cancer May Be Like Curing HIV -- and May Be As Difficult
- VRC01 Antibody Can Delay But Not Prevent HIV Rebound
- South African Child Has Controlled HIV Off Treatment for 8.5 Years
HIV Prevention
- Experts Agree that Intermittent Oral PrEP Probably Won't Work for Women
- Who Are Trans Women Acquiring HIV From?
- PrEP Use in U.S. Exceeds 100,000 in Gilead Pharmacy Survey
- Medical Male Circumcision for HIV Prevention Has Benefits for Women Too
- Another HIV Vaccine Efficacy Trial Will Start This Year
- Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa
- Study of Gay Couples Shows No Transmissions from Undetectable HIV+ Partners
- Long-Acting Cabotegravir Shows Promise For HIV Prevention
- PrEP Still Protected People Who Had Less Sex in Ipergay Study
HIV-Related Conditions and Comorbidities
- Switch from Boosted Protease Inhibitor to Dolutegravir Reduces Lipids in People with HIV
- Acute Kidney Injury Uncommon on Tenofovir, No Link Seen to Bone Breaks
- People with HIV Are at Risk for Liver Fibrosis and Steatosis
HIV Epidemiology and Access to Care
- Aim for $90-$90-$90 Target on HIV, Hepatitis, and TB Drug Prices, Study Says
- Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives
- WHO Recommends Urgent Care Package for People with Advanced HIV Disease
- World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
- New HIV Infections Halved as Treatment Scales Up in Swaziland
Hepatitis C and HIV/HCV Coinfection
- Glecaprevir/Pibrentasvir Effective for People with HIV/HCV Coinfection
- Hepatitis C Treatment is Effective and Feasible in Africa
IAS 2017: Study of Gay Men Shows No Transmissions from Undetectable HIV+ Partners
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
A study of 343 gay couples, where one partner had HIV and the other did not, has not found a single case of HIV transmission in 16,889 acts of condomless anal sex, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.
IAS 2017: World On Track To Reach 90-90-90 Targets for HIV Treatment by 2020
- Details
- Category: HIV/AIDS Epidemiology & Mortality
- Published on Friday, 28 July 2017 00:00
The world is on track to reach global targets for reducing AIDS deaths and expanding HIV treatment access by 2020, but some regions of the world risk falling further behind due to lack of political commitment, UNAIDS announced in the run-up tothe 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
IAS 2017: Long-Acting Cabotegravir + Rilpivirine Looks Good for HIV ART
- Details
- Category: HIV Treatment
- Published on Friday, 28 July 2017 00:00
Two long-acting injectable antiretrovirals, cabotegravir and rilpivirine, administered once every 4 or 8 weeks maintained viral suppression in about 90% of people who started therapy with an undetectable viral load, according to the latest results from the LATTE-2 trial, presented at the 9th International AIDS Society Conference on HIV Science this week in Paris and published simultaneously in The Lancet.
IAS 2017: Long-Acting Cabotegravir Shows Promise For HIV Prevention
- Details
- Category: HIV Prevention
- Published on Friday, 28 July 2017 00:00
A long-acting injectable formulation of cabotegravir given every 8 weeks produces high enough drugs levels in both men and women to offer protection against HIV, according to results from the HPTN 077 study presented this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. But another injectable prevention candidate, long-acting rilpivirine, has been abandoned.
IAS 2017: New HIV Integrase Inhibitor Bictegravir Works Well for First-Line Treatment
- Details
- Category: HIV Treatment
- Published on Friday, 28 July 2017 00:00
A single-tablet regimen containing the experimental integrase inhibitor bictegravir was as effective as 2 widely used approved regimens for first-time therapy in a pair of Phase 3 clinical trials, according to presentations at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris.
IAS 2017: New HIV Infections Halved as Treatment Scales Up in Swaziland
- Details
- Category: HIV Treatment
- Published on Friday, 28 July 2017 00:00
New HIV infections have been cut in half in Swaziland since 2011, at the same time as the proportion of people on antiretroviral treatment with fully suppressed viral load has doubled, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) this week in Paris. It is the first direct evidence that expanding HIV treatment results in fewer HIV infections in a country with a major epidemic, researchers said.
More Articles...
- IAS 2017: PrEP Still Protected People Who Had Less Sex in Ipergay Study
- IAS 2017: South African Child Has Controlled HIV Off Treatment for 8.5 Years
- IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report
- IAS 2017: IAS Conference on HIV Science Starts Sunday in Paris
- HR17: Combining Drug Addiction Treatment and Perinatal HIV Prevention Leads to Good Outcomes
Web Design and Development by